Two recent publications suggest modifications to standard subcutaneous daratumumab pre-meds is safe...and saves time!
Padmaraju et al experience from Chicago Med Center: https://doi.org/10.1093/oncolo/oyae158
Vazirnia et al experience from Mayo Clinic: https://doi.org/10.1200/OP.23.00470
We end summarizing some emerging evidence about the need, or lack thereof, for pre-paclitaxel H2RAs.
